Cargando…
NK cells from an AML patient have recovered in remission and reached comparable cytolytic activity to that of a healthy monozygotic twin mediated by the single-chain triplebody SPM-2
BACKGROUND: The capacity of patient’s Natural Killer cells (NKs) to be activated for cytolysis is an important prerequisite for the success of antibody-derived agents such as single-chain triplebodies (triplebodies) in cancer therapy. NKs recovered from AML patients at diagnosis are often found to b...
Autores principales: | Braciak, Todd A, Wildenhain, Sarah, Roskopf, Claudia C, Schubert, Ingo A, Fey, Georg H, Jacob, Uwe, Hopfner, Karl-Peter, Oduncu, Fuat S |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3842817/ https://www.ncbi.nlm.nih.gov/pubmed/24237598 http://dx.doi.org/10.1186/1479-5876-11-289 |
Ejemplares similares
-
P23. Efficient ex vivo lysis of acute myeloid leukaemic (AML) cells mediated by triplebodies with dual-targeting capability in conjunction with natural killer cells as effectors
por: Fey, G, et al.
Publicado: (2014) -
CD19-specific triplebody SPM-1 engages NK and γδ T cells for rapid and efficient lysis of malignant B-lymphoid cells
por: Schiller, Christian B., et al.
Publicado: (2016) -
Dual-targeting triplebody 33-16-123 (SPM-2) mediates effective redirected lysis of primary blasts from patients with a broad range of AML subtypes in combination with natural killer cells
por: Braciak, Todd A., et al.
Publicado: (2018) -
T cell-recruiting triplebody 19-3-19 mediates serial lysis of malignant B-lymphoid cells by a single T cell
por: Roskopf, Claudia C., et al.
Publicado: (2014) -
Dual-targeting triplebody 33-3-19 mediates selective lysis of biphenotypic CD19(+) CD33(+) leukemia cells
por: Roskopf, Claudia C., et al.
Publicado: (2016)